Author/Authors :
Yong Hou، نويسنده , , Luting Song، نويسنده , , Ping Zhu، نويسنده , , Bo Zhang، نويسنده , , Ye Tao، نويسنده , , Xun Xu، نويسنده , , Fuqiang Li، نويسنده , , Kui Wu، نويسنده , , Jie Liang، نويسنده , , Di Shao، نويسنده , , Hanjie Wu، نويسنده , , Xiaofei Ye، نويسنده , , Chen Ye، نويسنده , , Renhua Wu، نويسنده , , Min-Jian Wang، نويسنده , , Yan Chen، نويسنده , , Wei Xie، نويسنده , , Ruren Zhang، نويسنده , , Lei Chen، نويسنده , , Xin Liu، نويسنده , , et al.، نويسنده ,
Abstract :
Tumor heterogeneity presents a challenge for inferring clonal evolution and driver gene identification. Here, we describe a method for analyzing the cancer genome at a single-cell nucleotide level. To perform our analyses, we first devised and validated a high-throughput whole-genome single-cell sequencing method using two lymphoblastoid cell line single cells. We then carried out whole-exome single-cell sequencing of 90 cells from a JAK2-negative myeloproliferative neoplasm patient. The sequencing data from 58 cells passed our quality control criteria, and these data indicated that this neoplasm represented a monoclonal evolution. We further identified essential thrombocythemia (ET)-related candidate mutations such as SESN2 and NTRK1, which may be involved in neoplasm progression. This pilot study allowed the initial characterization of the disease-related genetic architecture at the single-cell nucleotide level. Further, we established a single-cell sequencing method that opens the way for detailed analyses of a variety of tumor types, including those with high genetic complex between patients.